In­otek shares crater (again) as an­oth­er glau­co­ma drug study flops

For the sec­ond time this year In­otek Phar­ma­ceu­ti­cals says its lead drug failed a clin­i­cal study for glau­co­ma. And the suc­ces­sive flop once again ham­mered its shares, which plunged 48% as it spi­raled in­to pen­ny stock sta­tus.

The news hit on Fri­day, af­ter the mar­ket $ITEK closed. The Lex­ing­ton, MA-based com­pa­ny not­ed a tem­po­rary and short-lived im­prove­ment in eye pres­sure among pa­tients tak­ing a com­bi­na­tion of tra­bo­deno­son and Xala­tan (la­tanoprost). But the la­tanoprost arm im­proved up to the cut­off point, while the com­bi­na­tion did not.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.